Use of Montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial

David B Price,Michel Y Rouleau,Christopher P Fletcher,Piyush Patel,Ronald Olivenstein,Leiv Myhr,J.Christian Virchow,W.R Cameron Aitchison,Ernst R Omenaas,Pam S Dellea,Martino Laurenzi,Jonathan A Leff

Current Therapeutic Research（2001）

引用 14|浏览14

暂无评分

摘要

Background: International asthma treatment guidelines recommend tapering inhaled corticosteroid (ICS) therapy to the lowest dose that provides the maximum effect. Montelukast, a leukotriene receptor antagonist with complementary anti-inflammatory actions, has been shown in a tightly controlled trial to allow effective tapering of ICS therapy.

查看译文

关键词

inhaled steroids,leukotriene receptor antagonists,montelukast,asthma,steroid sparing,steroid tapering

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要